Physician profile
Nathan W Scott
NPI 1174868095
$485.31
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $206.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.02 | 2021 | |
| Pfizer INC. | $54.70 | 2021 | |
| Lilly USA, LLC | $53.77 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $48.58 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $44.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.23 | 2022 | |
| Eisai INC. | $33.13 | 2021 | |
| Glaxosmithkline, LLC. | $31.77 | 2022 | |
| Sunovion Pharmaceuticals INC. | $24.69 | 2022 | |
| Astellas Pharma US INC | $23.88 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.